Cleveland Clinic
Cleveland Clinic

(c) Cleveland Clinic

News • Fat attenuation index

Biomarker helps to predict coronary inflammation

Researchers at Cleveland Clinic, University of Oxford, and University of Erlangen have identified a novel imaging biomarker – and found it can be used to predict all-cause and cardiac mortality by measuring inflammation of fatty tissue surrounding the coronary arteries.

Coronary artery inflammation inhibits fatty tissue formation surrounding the blood vessels, known as perivascular fat. Researchers developed the perivascular fat attenuation index (FAI) as an imaging biomarker to quantify inflammation-induced changes in perivascular fat. FAI captures coronary inflammation by mapping the changes in perivascular fat on coronary computed tomography angiography (CTA), enabling early detection of coronary inflammation.

“This is an exciting new technology which has the potential for providing a simple, non-invasive answer to detect patients at risk for future fatal heart attacks, said co-first author Milind Desai, M.D., a cardiologist at Ohio-headquartered Cleveland Clinic. “More importantly, it highlights the incredible value of cross-continent collaboration to validate the findings in different populations.”

The team behind the study, Cardiovascular Risk Prediction using Computed Tomography (CRISP-CT), collected data from two cohorts of consecutive patients undergoing coronary CT angiography — 1,872 patients in Germany from 2005 to 2009 (derivation cohort) and 2,040 patients at Cleveland Clinic from 2008 to 2016 (validation cohort). The median patient age of the cohorts was 62 and 53 years.

In both cohorts, higher perivascular FAI values — indicating greater coronary inflammation — were associated with significantly higher rates of death from any cause and death from cardiac causes. “This new technology may prove transformative for primary and secondary prevention. For the first time we have a set of biomarkers, derived from a routine test that is already used in everyday clinical practice, that measures what we call the ‘residual cardiovascular risk’, currently missed by all risk scores and non-invasive tests,” said Charalambos Antoniades, M.D., who led the study at the University of Oxford’s Division of Cardiovascular Medicine. “Knowing who is at increased risk for a heart attack could allow us to intervene early enough to prevent it. I expect these biomarkers to become an essential part of standard CT coronary angiography reporting in the coming years.”

Manifesting primarily as heart attacks and strokes, cardiovascular diseases (CVDs) take the lives of 17.7 million people every year – 31% of all global deaths – according to the World Health Organization.

11.09.2018

Read all latest stories

Related articles

Photo

News • Cardiology insights

Lab-grown heart cells 'mimic' disease in vitro

Heart cells from a patient with an inherited heart disease called arrhythmogenic cardiomyopathy do not contract correctly when grown in the laboratory, researchers from Osaka University have found.

Photo

News • microRNAs hint at cognitive decline

Researchers find warning signs for dementia in the blood

esearchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the blood that can indicate impending dementia. Their findings, which are presented in the…

Photo

News • Prognosis

Better heart failure outcomes through biomarker-based treatment

In a recent study by University of Alabama at Birmingham researchers, findings indicate that among patients with heart failure, obesity is associated with a higher risk of heart failure…

Related products

Shimadzu – LCMS-8060NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX (RUO)

Shimadzu Europa GmbH
Siemens Healthineers – Atellica VTLi

Cardiology

Siemens Healthineers – Atellica VTLi

Siemens Healthineers
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Subscribe to Newsletter